These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19541584)

  • 21. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
    Torres RA; Barr M; Thorn M; Gregory G; Kiely S; Chanin E; Carlo C; Martin M; Thornton J
    Am J Med; 1993 Dec; 95(6):573-83. PubMed ID: 8018144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group.
    Podzamczer D; Miró JM; Bolao F; Gatell JM; Cosín J; Sirera G; Domingo P; Laguna F; Santamaría J; Verdejo J
    Ann Intern Med; 1995 Aug; 123(3):175-80. PubMed ID: 7598298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initiating antiretroviral therapy within 2 weeks of anti-Pneumocystis treatment does not increase mortality or AIDS-defining events in patients with HIV-associated moderate to severe Pneumocystis pneumonia: results of a prospective observational multicenter study.
    Zeng YM; Li Y; Lu YQ; Liu M; Nie JM; Yuan J; Harypursat V; Zhou YH; Qin YY; Chen XH; Zhang YL; Zhang DF; Wang N; Chen H; Tian Q; Zhou Y; Qin YM; Yang XP; Chen YK
    BMC Pulm Med; 2022 Aug; 22(1):323. PubMed ID: 36008855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group.
    Derouin F; Leport C; Pueyo S; Morlat P; Letrillart B; Chêne G; Ecobichon JL; Luft B; Aubertin J; Hafner R; Vildé JL; Salamon R
    AIDS; 1996 Nov; 10(13):1521-7. PubMed ID: 8931787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical presentation and outcome of toxoplasmic encephalitis in patients with human immunodeficiency virus type 1 infection.
    Ho YC; Sun HY; Chen MY; Hsieh SM; Sheng WH; Chang SC
    J Microbiol Immunol Infect; 2008 Oct; 41(5):386-92. PubMed ID: 19122919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrence of Pneumocystis carinii pneumonia in an HIV-infected patient: apparent selective immune reconstitution after initiation of antiretroviral therapy.
    Crothers K; Huang L
    HIV Med; 2003 Oct; 4(4):346-9. PubMed ID: 14525547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy.
    Potter M; Odueyungbo A; Yang H; Saeed S; Klein MB;
    AIDS; 2010 Jul; 24(12):1857-65. PubMed ID: 20479633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group.
    Stansell JD; Osmond DH; Charlebois E; LaVange L; Wallace JM; Alexander BV; Glassroth J; Kvale PA; Rosen MJ; Reichman LB; Turner JR; Hopewell PC
    Am J Respir Crit Care Med; 1997 Jan; 155(1):60-6. PubMed ID: 9001290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoblot profile as predictor of toxoplasmic encephalitis in patients infected with human immunodeficiency virus.
    Leport C; Franck J; Chene G; Derouin F; Ecobichon JL; Pueyo S; Miro JM; Luft BJ; Morlat P; Dumon H;
    Clin Diagn Lab Immunol; 2001 May; 8(3):579-84. PubMed ID: 11329461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.
    Gerna G; Piccinini G; Genini E; Percivalle E; Zavattoni M; Lilleri D; Testa L; Comolli G; Maserati R; Baldanti F; Maccario R; Monforte AD; Revello MG
    J Acquir Immune Defic Syndr; 2001 Dec; 28(4):320-31. PubMed ID: 11707667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical presentation and outcome of toxoplasma encephalitis in HIV-infected patients from Zaria, Northern Nigeria: a case series of 9 patients.
    Ogoina D; Obiako RO; Onyemelukwe GC; Musa BO; Hamidu AU
    J Int Assoc Provid AIDS Care; 2014; 13(1):18-21. PubMed ID: 23962913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
    Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
    N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.
    Kirk O; Reiss P; Uberti-Foppa C; Bickel M; Gerstoft J; Pradier C; Wit FW; Ledergerber B; Lundgren JD; Furrer H;
    Ann Intern Med; 2002 Aug; 137(4):239-50. PubMed ID: 12186514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects.
    Barry SM; Lipman MC; Deery AR; Johnson MA; Janossy G
    HIV Med; 2002 Jul; 3(3):207-11. PubMed ID: 12139660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
    Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
    Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
    Goldie SJ; Kaplan JE; Losina E; Weinstein MC; Paltiel AD; Seage GR; Craven DE; Kimmel AD; Zhang H; Cohen CJ; Freedberg KA
    Arch Intern Med; 2002 Apr; 162(8):921-8. PubMed ID: 11966344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.
    D'Amico R; Yang Y; Mildvan D; Evans SR; Schnizlein-Bick CT; Hafner R; Webb N; Basar M; Zackin R; Jacobson MA
    J Clin Immunol; 2005 Mar; 25(2):106-15. PubMed ID: 15821887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection.
    Lok JJ; Bosch RJ; Benson CA; Collier AC; Robbins GK; Shafer RW; Hughes MD;
    AIDS; 2010 Jul; 24(12):1867-76. PubMed ID: 20467286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
    Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
    Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.